| Primary |
| Acute Lymphocytic Leukaemia |
67.7% |
| Drug Use For Unknown Indication |
10.3% |
| B Precursor Type Acute Leukaemia |
5.2% |
| Product Used For Unknown Indication |
2.9% |
| Acute Lymphocytic Leukemia |
1.9% |
| Chemotherapy |
1.7% |
| T-cell Type Acute Leukaemia |
1.7% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.1% |
| Non-hodgkin's Lymphoma |
1.0% |
| Systemic Candida |
1.0% |
| Chronic Lymphocytic Leukaemia |
0.8% |
| Multiple Myeloma |
0.8% |
| Precursor B-lymphoblastic Lymphoma |
0.8% |
| Diffuse Large B-cell Lymphoma |
0.6% |
| Leukaemia |
0.6% |
| T-cell Lymphoma |
0.5% |
| Acute Leukaemia |
0.3% |
| Acute Lymphocytic Leukaemia Recurrent |
0.3% |
| Peritoneal Carcinoma |
0.3% |
| Transitional Cell Carcinoma |
0.3% |
|
| Vomiting |
24.4% |
| Urticaria |
13.4% |
| Pancreatitis |
7.3% |
| Anaphylactic Reaction |
6.1% |
| Pyrexia |
4.9% |
| Infusion Related Reaction |
4.3% |
| Hyperglycaemia |
3.7% |
| Wheezing |
3.7% |
| Platelet Count Decreased |
3.0% |
| Rash |
3.0% |
| Respiratory Distress |
3.0% |
| Swelling Face |
3.0% |
| Thrombocytopenia |
3.0% |
| Hypersensitivity |
2.4% |
| Infection |
2.4% |
| Liver Function Test Abnormal |
2.4% |
| Pleural Effusion |
2.4% |
| Renal Failure |
2.4% |
| Shock |
2.4% |
| Subarachnoid Haemorrhage |
2.4% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
63.0% |
| B Precursor Type Acute Leukaemia |
13.8% |
| Natural Killer-cell Lymphoblastic Lymphoma |
5.0% |
| Product Used For Unknown Indication |
4.4% |
| Precursor B-lymphoblastic Lymphoma |
3.5% |
| T-cell Type Acute Leukaemia |
2.1% |
| Drug Use For Unknown Indication |
1.8% |
| Prophylaxis |
1.8% |
| Multiple Myeloma |
0.9% |
| Chemotherapy |
0.6% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
0.6% |
| Acute Leukaemia |
0.3% |
| Acute Lymphocytic Leukaemia Recurrent |
0.3% |
| Antacid Therapy |
0.3% |
| Cardiac Arrest |
0.3% |
| Leukaemia |
0.3% |
| Leukaemic Infiltration Brain |
0.3% |
| Nausea |
0.3% |
| Pain |
0.3% |
| Stomatitis |
0.3% |
|
| Pyrexia |
15.9% |
| Vomiting |
13.0% |
| Anaphylactic Reaction |
7.2% |
| Death |
7.2% |
| Blood Bilirubin Increased |
5.8% |
| White Blood Cell Count Decreased |
5.8% |
| Hepatic Encephalopathy |
4.3% |
| Hypertension |
4.3% |
| Urticaria |
4.3% |
| Alanine Aminotransferase Increased |
2.9% |
| Blood Glucose Increased |
2.9% |
| Disseminated Intravascular Coagulation |
2.9% |
| Febrile Neutropenia |
2.9% |
| Hyperglycaemia |
2.9% |
| Hypertriglyceridaemia |
2.9% |
| Hypotension |
2.9% |
| Neutropenia |
2.9% |
| Pancreatitis |
2.9% |
| Pleural Effusion |
2.9% |
| Proteinuria |
2.9% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
33.3% |
| Chromosome Analysis Abnormal |
24.2% |
| Hepatosplenic T-cell Lymphoma |
15.2% |
| Lymphoma |
6.1% |
| Product Used For Unknown Indication |
6.1% |
| Prophylaxis Against Graft Versus Host Disease |
6.1% |
| Acute Lymphocytic Leukaemia Recurrent |
3.0% |
| Bronchopulmonary Aspergillosis |
3.0% |
| Drug Use For Unknown Indication |
3.0% |
|
| Gastrointestinal Haemorrhage |
12.5% |
| Spinal Shock |
12.5% |
| Gastrointestinal Toxicity |
6.3% |
| Grand Mal Convulsion |
6.3% |
| Haemorrhage |
6.3% |
| Hyperglycaemia |
6.3% |
| Hypertension |
6.3% |
| Paraesthesia |
6.3% |
| Skin Depigmentation |
6.3% |
| Skin Ulcer |
6.3% |
| Somnolence |
6.3% |
| Transverse Sinus Thrombosis |
6.3% |
| Upper Respiratory Tract Infection |
6.3% |
| Vomiting |
6.3% |
|
